ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Go back to ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis| CHEMOCENTRYX (NASDAQ: CCXI) | Delayed: 51.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.99 | 52 Week High | $8.30 | |||
| Open | $51.99 | 52 Week Low | $1.92 | |||
| Day High | $51.99 | P/E | N/A | |||
| Day Low | $51.99 | EPS | $-1.00 | |||
| Volume | 1,216 | |||||
